Bone microdamage: a clinical perspective
The DOI matches its Crossref record; 86 of the 87 references it cites were found in a registry or an index.
Abstract
Introduction Microdamage accumulation due to fatigue loading may lead to fracture. In addition, several studies using animal models have suggested in recent years that bisphosphonates might increase microdamage accumulation.Methods We have reviewed the literature after a PubMed search, to examine the techniques to look for microcracks, the relationship between microdamage and bone strength, and the influence of anti-osteoporosis agents.Results Currently, the search for microcracks relies on bulk staining of bone samples, which are then examined on optic microscopy and fluorescence or confocal microscopy. The accumulation of microdamage is associated with fatigue loading and is likely to trigger targeted bone remodeling, especially in cortical bone. Several studies examining beagle dogs receiving bisphosphonates have shown a dose-dependent accumulation of microdamage in bone, with conflicting results regarding the consequences on bone mechanical properties. In living humans, obtaining data is limited to the iliac crest bone. The potential association between long-term bisphosphonate use and microcrack accumulation at the iliac crest bone has not been established unequivocally.Conclusions Bone microdamage is critical in the understanding of bone quality. Assessment of microdamage is technically difficult, especially in humans. The clinical impact of microdamage potentially induced by bone drugs has not been established in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and there is concern that long-term use of antiresorptive therapies can result in decreased toughness (48, 72, 73).”
From Bone Mechanical Properties in Healthy and Diseased States (2018) · cites this paper as [73]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407 · cited 1×
“This is because bone turnover was shown to reach a steady state after 1 year of alendronate use [81, 82].”
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
CENTRAL OBESITY AND CORONARY HEART DISEASE IN MEN
Donahue, R., & Abbott, R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91357-2 · Cited by 818
Bone remodeling in response to in vivo fatigue microdamage
Burr, D. B., Martin, R. B., Schaffler, M. B., & Radin, E. L. (1985) · Journal of Biomechanics · doi:10.1016/0021-9290(85)90204-0 · Cited by 765 · cited 4×
“Osteoclastic bone resorption following fatigue is also associated spatially with regions of osteocyte apoptosis [5, 6, 60].”
InfluentialVerborgt, O., Gibson, G. J., & Schaffler, M. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.60 · Cited by 731 · cited 3×
“Osteoclastic bone resorption following fatigue is also associated spatially with regions of osteocyte apoptosis [5, 6, 60].”
Mashiba, T., Hirano, T., Turner, C. H., Forwood, M. R., Johnston, C. C., & Burr, D. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.613 · Cited by 688 · cited 1×
“0 mg/kg/day), or saline, daily, for 1 year [10].”
Increased intracortical remodeling following fatigue damage
Mori, S., & Burr, D. B. (1993) · Bone · doi:10.1016/8756-3282(93)90235-3 · Cited by 559 · cited 4×
“Osteoclastic bone resorption following fatigue is also associated spatially with regions of osteocyte apoptosis [5, 6, 60].”
Influential
Research works printed but not linked: 3
- Mori S, Burr DB (1993) Increased intracortical remodeling following fatigue damage. Bone 14:103–109 · DOI · Paper page
- Tschantz P, Rutishauser E (1967) La surcharge mécanique de l'os vivant. Ann Anat Path 12:223–248
- Flora L, Hassing GS, Parfitt AM, Villaneuva AR (1980) Comparative skeletal effects of two diphosphonates in dogs. Met Bone Dis 2:S389–S407
Cited by
Bone Mechanical Properties in Healthy and Diseased States
Morgan, E. F., Unnikrisnan, G. U., & Hussein, A. I. (2018) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-062117-121139 · Cited by 1,026
“The mechanical effects of osteoporosis therapies, however, differ among the types of therapy (70, 71), and there is concern that long-term use of antiresorptive therapies can result in decreased toughness (48, 72, 73).”
Denosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 715
“Whether microdamage accumulation occurs in postmenopausal women treated long term with bisphosphonates remains controversial [143,144].”
BackgroundBone composition: relationship to bone fragility and antiosteoporotic drug effects
Boskey, A. L. (2013) · BoneKEy Reports · doi:10.1038/bonekey.2013.181 · Cited by 424
“‘Bone quality’ factors include composition (weight percent of each component), mineralization (organization of the mineral and its crystallite size and perfection), collagen content and collagen crosslinks, morphology,(10) microarchitecture(11) and the presence of microcracks.(12) Each of these factors varies with hea…”
BackgroundHigh-resolution Computed Tomography for Clinical Imaging of Bone Microarchitecture
Burghardt, A. J., Link, T. M., & Majumdar, S. (2011) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-010-1766-x · Cited by 296
“BMD only explains about 70% to 75% of the variance in strength [2], while the remaining variance is due to the cumulative and synergistic effect of factors such as bone macro- and microarchitecture, tissue composition, and microdamage [30, 132].”
Pathria, M. N., Chung, C. B., & RESNICK, D. L. (2016) · Radiology · doi:10.1148/radiol.16142305 · Cited by 161
Metadata
- Authors
- Chapurlat, R. D., & Delmas, P. D.
- Affiliations
- Inserm (FR)
- Corresponding author
- Chapurlat, R. D.
- ORCID
- Chapurlat, R. D.
- Venue
- Osteoporosis International
- Published
- 2009-03-17
- Volume
- 20
- Issue
- 8
- Pages
- 1299-1308
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2046897120
- Cited by
- 85
- References
- 87
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 6 · 2022: 2 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 9 · 2016: 8 · 2015: 7 · 2014: 4 · 2013: 6 · 2012: 9
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- bone microcracks, microdamage accumulation, fatigue loading, fracture risk, bisphosphonates, bone quality, bone strength, cortical bone, iliac crest bone, anti-osteoporosis agents, confocal microscopy, fluorescence microscopy
- MeSH terms
- Animals, Disease Models, Animal, Dogs, Female, Humans, Osteocytes, Osteoporosis, Postmenopausal, Fractures, Stress, Bone Remodeling, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.